Evidence map›Paper›PMID 41899626›Full record

ArticleCancers2026

Efficacy and Safety of Dalpiciclib in HR-Positive Advanced Breast Cancer: A Two-Center Retrospective Study.

Jingjing Li, Zhiqiang Zong, Didi Zhu, Xiaojun Xu, Yunwen Yan, Jia Li, Fanfan Li, Jiqing Hao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jingjing LiDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, China.
Zhiqiang ZongDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, China.
Didi ZhuDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, China.
Xiaojun XuDepartment of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, China.
Yunwen YanDepartment of Breast Surgery, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, China.
Jia LiDepartment of Breast Surgery, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, China.
Fanfan LiDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, No. 678 Furong Road, Hefei 230601, China.
Jiqing HaoDepartment of Oncology, The First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Hefei 230022, China.

Funding

Anhui Province Key Research and Development Plan 2022e07020038Research Fund of Anhui Institute of translational medicine 2023zhyx-C65)
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CDK4/6 inhibitorDalpiciclibendocrine therapyHR-positive breast cancerprogression-free survival

Identifiers

PMID41899626
PMCPMC13025841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.